miR-30d-5p promotes beta cell recovery and immunomodulation in type 1 diabetes - Summary - MDSpire

miR-30d-5p promotes beta cell recovery and immunomodulation in type 1 diabetes

  • By

  • Laia Gomez-Muñoz

  • David Perna-Barrull

  • Dagmar Klein

  • Silvia Alvarez-Cubela

  • Gerard Godoy-Tena

  • Daniel A Cook

  • Catalina Quimper Voto-Bernales

  • Mayur Doke

  • Marta Murillo

  • Aina Valls

  • Ricardo Luis Pastori

  • Juan Dominguez-Bendala

  • Marta Vives-Pi

  • June 2, 2026

  • 0 min

Share

Objective:

To investigate the role of miR-30d-5p in immune regulation and beta cell recovery during the partial remission phase of Type 1 diabetes, which is crucial for understanding potential therapeutic strategies.

Key Findings:
  • miR-30d-5p enhances insulin secretion and promotes the emergence of insulin-producing cells, as evidenced by functional assays.
  • Treatment with miR-30d-5p in NOD mice delayed diabetes onset, indicating potential protective effects.
  • miR-30d-5p increased expression of inhibitory molecules in human T lymphocytes and modulated interferon-gamma secretion, suggesting a role in immune regulation.
Interpretation:

miR-30d-5p may play a significant role in immune cell regulation and beta cell recovery processes in Type 1 diabetes, highlighting its potential as a therapeutic target.

Limitations:
  • The study primarily utilized animal models and human samples, which may not fully replicate clinical scenarios, limiting the generalizability of the findings.
  • Further research is needed to confirm the therapeutic potential of miR-30d-5p and its mechanisms of action in diverse populations.
Conclusion:

The findings support the potential of miR-30d-5p as a therapeutic target for preserving beta cell function in Type 1 diabetes, warranting further investigation into its clinical applications.

Original Source(s)

miR-30d-5p promotes beta cell recovery and immunomodulation in type 1 diabetes

  • by Laia Gomez-Muñoz, David Perna-Barrull, Dagmar Klein, Silvia Alvarez-Cubela, Gerard Godoy-Tena, Daniel A Cook, Catalina Quimper Voto-Bernales, Mayur Doke, Marta Murillo, Aina Valls, Ricardo Luis Pastori, Juan Dominguez-Bendala, Marta Vives-Pi

  • June 2, 2026

Related Content

Does Metabolic and Bariatric Surgery Reduce the Risk of Developing Parkinson’s Disease: A Propensity Score Matching Analysis Using Data from the National Inpatient Sample

Editorial: Addressing the Challenges of Diabetes Complications and Exploring Innovative Approaches

Retinal Age Model Tied to Disease Risk

Fundus-based tool estimates biologic aging but shows modest gains over prior models